ALS/FTLD: experimental models and reality

被引:0
|
作者
Rachel H. Tan
Yazi D. Ke
Lars M. Ittner
Glenda M. Halliday
机构
[1] Neuroscience Research Australia,School of Medical Sciences
[2] University of NSW,Brain and Mind Centre, Sydney Medical School
[3] the University of Sydney,Motor Neuron Disease Unit, Department of Anatomy, Faculty of Medicine
[4] University of NSW,Dementia Research Unit, Department of Anatomy, Faculty of Medicine
[5] University of NSW,undefined
来源
Acta Neuropathologica | 2017年 / 133卷
关键词
Amyotrophic lateral sclerosis; C9orf72; Frontotemporal lobar degeneration; Microtubule associated protein tau; Superoxide dismutase 1; tar DNA-binding protein 43;
D O I
暂无
中图分类号
学科分类号
摘要
Amyotrophic lateral sclerosis is characterised by a loss of upper and lower motor neurons and characteristic muscle weakness and wasting, the most common form being sporadic disease with neuronal inclusions containing the tar DNA-binding protein 43 (TDP-43). Frontotemporal lobar degeneration is characterised by atrophy of the frontal and/or temporal lobes, the most common clinical form being the behavioural variant, in which neuronal inclusions containing either TDP-43 or 3-repeat tau are most prevalent. Although the genetic mutations associated with these diseases have allowed various experimental models to be developed, the initial genetic forms identified remain the most common models employed to date. It is now known that these first models faithfully recapitulate only some aspects of these diseases and do not represent the majority of cases or the most common overlapping pathologies. Newer models targeting the main molecular pathologies are still rare and in some instances, lack significant aspects of the molecular pathology. However, these diseases are complex and multigenic, indicating that experimental models may need to be targeted to different disease aspects. This would allow information to be gleaned from a variety of different yet relevant models, each of which has the capacity to capture a certain aspect of the disease, and together will enable a more complete understanding of these complex and multi-layered diseases.
引用
收藏
页码:177 / 196
页数:19
相关论文
共 50 条
  • [11] Recent Advances in the Genetics of the ALS-FTLD Complex
    Huw R. Morris
    Adrian J. Waite
    Nigel M. Williams
    James W. Neal
    Derek J. Blake
    Current Neurology and Neuroscience Reports, 2012, 12 : 243 - 250
  • [12] Towards a TDP-43-Based Biomarker for ALS and FTLD
    Feneberg, Emily
    Gray, Elizabeth
    Ansorge, Olaf
    Talbot, Kevin
    Turner, Martin R.
    MOLECULAR NEUROBIOLOGY, 2018, 55 (10) : 7789 - 7801
  • [13] Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43
    Walker, Adam K.
    Spiller, Krista J.
    Ge, Guanghui
    Zheng, Allen
    Xu, Yan
    Zhou, Melissa
    Tripathy, Kalyan
    Kwong, Linda K.
    Trojanowski, John Q.
    Lee, Virginia M. -Y.
    ACTA NEUROPATHOLOGICA, 2015, 130 (05) : 643 - 660
  • [14] ALS and FTLD: two faces of TDP-43 proteinopathy
    Liscic, R. M.
    Grinberg, L. T.
    Zidar, J.
    Gitcho, M. A.
    Cairns, N. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 (08) : 772 - 780
  • [15] Disease-modifying effects of metabolic perturbations in ALS/FTLD
    Jawaid, Ali
    Khan, Romesa
    Polymenidou, Magdalini
    Schulz, Paul E.
    MOLECULAR NEURODEGENERATION, 2018, 13
  • [16] Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD
    Feneberg, Emily
    Steinacker, Petra
    Volk, Alexander Erich
    Weishaupt, Jochen Hans
    Wollmer, Marc Axel
    Boxer, Adam
    Tumani, Hayrettin
    Ludolph, Albert Christian
    Otto, Markus
    JOURNAL OF NEURAL TRANSMISSION, 2016, 123 (03) : 289 - 296
  • [17] Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD
    Tamaki, Yoshitaka
    Urushitani, Makoto
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (20)
  • [18] Structure of pathological TDP-43 filaments from ALS with FTLD
    Arseni, Diana
    Hasegawa, Masato
    Murzin, Alexey G.
    Kametani, Fuyuki
    Arai, Makoto
    Yoshida, Mari
    Ryskeldi-Falcon, Benjamin
    NATURE, 2022, 601 (7891) : 139 - +
  • [19] The FUS about arginine methylation in ALS and FTLD
    Kaneb, Hannah M.
    Dion, Patrick A.
    Rouleau, Guy A.
    EMBO JOURNAL, 2012, 31 (22) : 4249 - 4251
  • [20] Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy
    Arai, Tetsuaki
    Hasegawa, Masato
    Nonoka, Takashi
    Kametani, Fuyuki
    Yamashita, Makiko
    Hosokawa, Masato
    Niizato, Kazuhiro
    Tsuchiya, Kuniaki
    Kobayashi, Zen
    Ikeda, Kenji
    Yoshida, Mari
    Onaya, Mitsumoto
    Fujishiro, Hiroshige
    Akiyama, Haruhiko
    NEUROPATHOLOGY, 2010, 30 (02) : 170 - 181